CareDx (CDNA) Reports Q4 Revenue of $108 Million, Up 25% YoY

Written by Emily J. Thompson, Senior Investment Analyst

CDNA+1.66%

Source: NASDAQ.COM

Updated: Jan 12 2026

0mins

Source: NASDAQ.COM

Significant Revenue Growth: CareDx reported preliminary Q4 revenue of approximately $108 million, reflecting a 25% year-over-year increase, indicating strong market performance that is likely to boost investor confidence.
Testing Services Revenue Rise: Testing services revenue reached approximately $78 million, up 23% year-over-year, demonstrating ongoing growth in the company's core business and enhancing its competitive position.
Increase in Testing Volume: The volume of testing services approximated 53,000, marking a 17% increase, which reflects rising customer demand and could drive future revenue growth.
Optimistic 2025 Outlook: Preliminary projections for 2025 revenue stand at approximately $380 million, a 14% year-over-year increase, showcasing the company's confidence in future growth, particularly in the expansion of testing services.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like CDNA with instant alerts to capture every critical market movement.

Sign up for free to build your custom watchlist and receive professional-grade stock notifications.

CDNA

$20.8+Infinity%1D

Analyst Views on CDNA

Wall Street analysts forecast CDNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDNA is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Analyst Rating

1 Buy

3 Hold

0 Sell

Hold

Current: 20.460

Low

18.00

Averages

18.00

High

18.00

Current: 20.460

Low

18.00

Averages

18.00

High

18.00

Craig-Hallum

Buy

to

Hold

downgrade

$26

2026-01-06

Reason

Craig-Hallum

Price Target

$26

AI Analysis

2026-01-06

downgrade

Buy

to

Hold

Reason

Craig-Hallum downgraded CareDx to Hold from Buy with a $26 price target.

Craig-Hallum

Buy

to

Hold

downgrade

$26

2026-01-06

Reason

Craig-Hallum

Price Target

$26

2026-01-06

downgrade

Buy

to

Hold

Reason

As previously reported, Craig-Hallum downgraded CareDx to Hold from Buy with a $26 price target. With the shares having fully recovered to where they were before MolDX issued its restrictive draft LCD back in July, the firm believes the risk-reward appears less compelling. At this point, 2026 revenue and longer-term growth will be highly dependent on the shape of the final LCD. Craig-Hallum can conceive of a scenario where next year's numbers are too high and longer-term growth opportunities are less robust than it once believed. In the meantime, the firm won't be shocked if the Q4 2025 volume falls below the midpoint of management's guidance.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CDNA

Unlock Now

About CDNA

CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.